Latest Insider Transactions at Revance Therapeutics, Inc. (RVNC)
This section provides a real-time view of insider transactions for Revance Therapeutics, Inc. (RVNC). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Revance Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Revance Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 06
2025
|
Julian S Gangolli |
SELL
Sale (or disposition) back to the issuer
|
Direct |
15,000
-100.0%
|
-
|
|
Feb 06
2025
|
Carey O Connor Kolaja |
SELL
Sale (or disposition) back to the issuer
|
Direct |
15,000
-100.0%
|
-
|
|
Feb 06
2025
|
Olivia C Ware |
SELL
Sale (or disposition) back to the issuer
|
Direct |
15,000
-100.0%
|
-
|
|
Feb 06
2025
|
Erica Jordan Chief Commercial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
107,942
-100.0%
|
-
|
|
Feb 06
2025
|
David Hollander CMO & Global Therapeutics Lead |
SELL
Sale (or disposition) back to the issuer
|
Direct |
95,212
-100.0%
|
-
|
|
Feb 06
2025
|
Dwight Moxie CLO & GC |
SELL
Sale (or disposition) back to the issuer
|
Direct |
114,104
-100.0%
|
-
|
|
Feb 06
2025
|
Dwight Moxie CLO & GC |
BUY
Grant, award, or other acquisition
|
Direct |
18,125
+50.0%
|
-
|
|
Feb 06
2025
|
Tobin Schilke CFO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
124,438
-100.0%
|
-
|
|
Feb 06
2025
|
Tobin Schilke CFO |
BUY
Grant, award, or other acquisition
|
Direct |
20,883
+50.0%
|
-
|
|
Feb 06
2025
|
Mark J Foley President & CEO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
112,619
-100.0%
|
-
|
|
Feb 06
2025
|
Mark J Foley President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
84,686
+50.0%
|
-
|
|
Feb 06
2025
|
Angus C. Russell |
SELL
Sale (or disposition) back to the issuer
|
Direct |
15,000
-100.0%
|
-
|
|
Feb 06
2025
|
Chris Nolet |
SELL
Sale (or disposition) back to the issuer
|
Direct |
15,000
-100.0%
|
-
|
|
Feb 06
2025
|
Jill Beraud |
SELL
Sale (or disposition) back to the issuer
|
Direct |
15,000
-100.0%
|
-
|
|
Feb 06
2025
|
Vlad Coric |
SELL
Sale (or disposition) back to the issuer
|
Direct |
15,000
-100.0%
|
-
|
|
Feb 04
2025
|
Julian S Gangolli |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
30,106
-66.75%
|
$90,318
$3.65 P/Share
|
|
Feb 04
2025
|
Carey O Connor Kolaja |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
16,561
-52.47%
|
$49,683
$3.65 P/Share
|
|
Feb 04
2025
|
Olivia C Ware |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
16,675
-52.64%
|
$50,025
$3.65 P/Share
|
|
Feb 04
2025
|
Erica Jordan Chief Commercial Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
6,922
-6.03%
|
$20,766
$3.65 P/Share
|
|
Feb 04
2025
|
David Hollander CMO & Global Therapeutics Lead |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
9,733
-9.27%
|
$29,199
$3.65 P/Share
|
|
Feb 04
2025
|
Dwight Moxie CLO & GC |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
47,815
-33.25%
|
$143,445
$3.65 P/Share
|
|
Feb 04
2025
|
Tobin Schilke CFO |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
97,999
-48.62%
|
$293,997
$3.65 P/Share
|
|
Feb 04
2025
|
Mark J Foley President & CEO |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
110,913
-100.0%
|
$332,739
$3.65 P/Share
|
|
Feb 04
2025
|
Mark J Foley President & CEO |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
996,935
-97.27%
|
$2,990,805
$3.65 P/Share
|
|
Feb 04
2025
|
Angus C. Russell |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
36,506
-70.88%
|
$109,518
$3.65 P/Share
|
|
Feb 04
2025
|
Chris Nolet |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
28,606
-65.6%
|
$85,818
$3.65 P/Share
|
|
Feb 04
2025
|
Jill Beraud |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
28,606
-65.6%
|
$85,818
$3.65 P/Share
|
|
Feb 04
2025
|
Vlad Coric |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
5,784
-27.83%
|
$17,352
$3.65 P/Share
|
|
Feb 03
2025
|
Dwight Moxie CLO & GC |
BUY
Grant, award, or other acquisition
|
Direct |
5,979
+3.99%
|
-
|
|
Feb 03
2025
|
Tobin Schilke CFO |
BUY
Grant, award, or other acquisition
|
Direct |
6,888
+3.3%
|
-
|
|
Feb 03
2025
|
Mark J Foley President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
27,933
+2.65%
|
-
|
|
Dec 31
2024
|
Mark J Foley President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
1,000
+0.1%
|
$2,000
$2.18 P/Share
|
|
Dec 31
2024
|
Tobin Schilke CFO |
BUY
Grant, award, or other acquisition
|
Direct |
1,000
+0.51%
|
$2,000
$2.18 P/Share
|
|
Nov 18
2024
|
David Hollander CMO & Global Therapeutics Lead |
SELL
Open market or private sale
|
Direct |
3,908
-3.59%
|
$15,632
$4.17 P/Share
|
|
Jun 30
2024
|
Tobin Schilke CFO |
BUY
Grant, award, or other acquisition
|
Direct |
1,000
+0.51%
|
$2,000
$2.18 P/Share
|
|
Jun 30
2024
|
Mark J Foley President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
1,000
+0.1%
|
$2,000
$2.18 P/Share
|
|
May 01
2024
|
Julian S Gangolli |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+24.96%
|
-
|
|
May 01
2024
|
Carey O Connor Kolaja |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+32.22%
|
-
|
|
May 01
2024
|
Chris Nolet |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+25.59%
|
-
|
|
May 01
2024
|
Angus C. Russell |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+22.55%
|
-
|
|
May 01
2024
|
Olivia C Ware |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+32.14%
|
-
|
|
May 01
2024
|
Jill Beraud |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+25.59%
|
-
|
|
May 01
2024
|
Vlad Coric |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+41.92%
|
-
|
|
Apr 16
2024
|
Erica Jordan Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
2,392
-2.04%
|
$7,176
$3.8 P/Share
|
|
Mar 18
2024
|
Dwight Moxie CLO & GC |
SELL
Open market or private sale
|
Direct |
8,125
-5.57%
|
$40,625
$5.04 P/Share
|
|
Mar 18
2024
|
Dustin S Sjuts President |
SELL
Open market or private sale
|
Direct |
9,211
-5.21%
|
$46,055
$5.04 P/Share
|
|
Mar 18
2024
|
Tobin Schilke CFO |
SELL
Open market or private sale
|
Direct |
9,361
-4.63%
|
$46,805
$5.04 P/Share
|
|
Mar 15
2024
|
Dwight Moxie CLO & GC |
SELL
Payment of exercise price or tax liability
|
Direct |
3,269
-2.19%
|
$16,345
$5.3 P/Share
|
|
Mar 15
2024
|
Dustin S Sjuts President |
SELL
Payment of exercise price or tax liability
|
Direct |
2,967
-1.65%
|
$14,835
$5.3 P/Share
|
|
Mar 15
2024
|
Mark J Foley President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
20,533
-1.01%
|
$102,665
$5.3 P/Share
|